Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/09/17
End: 05/09/25
Due: 05/09/26
Phase: N/A
Priority: Normal
Start: 12/31/15
End: 10/16/20
Due: 10/16/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer | NCT03691012 | Walter and Eliza Hall Institute of Medical Research | user2@example.com | None | 2017-05-09 | 2025-05-09 | 2026-05-09 | - | - | 2025-07-14 |
| Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours | NCT04122430 | Walter and Eliza Hall Institute of Medical Research | user2@example.com | None | 2015-12-31 | 2020-10-16 | 2021-10-16 | - | - | 2025-07-14 |